Investigation of clinical characteristics and genome associations in the 'UK Lipoedema' cohort

Authors

Dionysios Grigoriadis^{1*}, Ege Sackey^{1*}, Katie Riches^{2**}, Malou van Zanten^{1**}, Glen Brice³, Ruth England², Mike Mills¹, Sara E Dobbins¹, Lipoedema Consortium, Genomics England Research Consortium⁴, Steve Jeffery¹, Liang Dong⁵, David B. Savage⁵, Peter S. Mortimer^{1,6}, Vaughan Keeley^{2,7}, Alan Pittman¹, Kristiana Gordon^{1,6‡}, Pia Ostergaard^{1‡}

Affiliations

1. Molecular and Clinical Sciences Institute, St George's University of London, London, UK
2. University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK
3. South West Thames Regional Genetics Unit, St George's University of London, London, UK
4. Genomics England, London, UK
5. Metabolic Research Laboratories, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK
6. Dermatology & Lymphovascular Medicine, St George's Universities NHS Foundation trust, London, UK
7. University of Nottingham Medical School, Nottingham, UK

*These two authors contributed equally; ** These two authors contributed equally

‡Clinical correspondence to Kristiana Gordon kristiana.gordon@stgeorges.nhs.uk and research-related correspondence to Pia Ostergaard, posterga@sgul.ac.uk

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Lipoedema is a chronic adipose tissue disorder mainly affecting women, causing excess subcutaneous fat deposition on the lower limbs with pain and tenderness. There is often a family history of lipoedema, suggesting a genetic origin, but the contribution of genetics is currently unclear. A tightly phenotyped cohort of 200 lipoedema patients was recruited from two UK specialist clinics. Objective clinical characteristics and measures of quality of life data were obtained. In an attempt to understand the genetic architecture of the disease better, genome-wide single nucleotide polymorphism (SNP) genotype data were obtained, and a genome wide association study (GWAS) performed on 130 of the recruits. The analysis revealed genetic loci suggestively associated with the lipoedema phenotype, with further support provided by an independent cohort taken from the 100,000 Genomes Project. Top SNPs included loci associated with lipoma formation, biosynthesis of hormones and lipid hydroxylation. Exactly how these SNPs relate to a lipoedema disease mechanism is not yet understood but the findings are consistent with existing fat and hormone hypotheses. This first GWAS of a UK lipoedema cohort has identified genetic regions of suggestive association with the disease. Further replication of these findings in different populations is warranted.

Introduction

Lipoedema is a chronic condition characterized by abnormal subcutaneous accumulation of adipose tissue in the limbs. This condition predominantly affects women, and the clinical phenotype is of a disproportionate figure with symmetrically enlarged lower body, typically affecting the hips and buttocks, extending to the legs, with sparing of the feet leading to a bracelet or cuffing effect at the ankles. Some patients have a more proximal distribution of abnormal fat, with the thighs affected to a greater extent than the lower legs. The affected tissues feel soft and “doughy” to the touch and the skin remains soft unlike in lymphoedema. In some patients the abnormal fat is reported to feel grainy, nodular or like “beans in a bag” [1, 2]. The torso appears unaffected, and, in the absence of obesity, individuals present with a relatively small waist and chest. The upper limbs may also be involved, but with forearm sparing in many cases. The onset of lipoedema often occurs at times of female hormonal change such as puberty, during pregnancy or menopause [3, 4]. The condition is associated with easy bruising, tenderness when touched, and chronic pain in the affected limbs [5]. The pain is frequently misdiagnosed as fibromyalgia. Chronic fatigue, psychosocial and poor body image issues are recognized comorbidities with lipoedema.

The term lipoedema itself causes confusion amongst medical professionals. Whilst it is derived from Latin and Greek words for “fat” (lipid or lipos) and “to swell” (oedema or oidein), physicians tend to use the term “oedema” in clinical practice to refer to the presence of fluid swelling. Lipoedema remains largely underdiagnosed or even misdiagnosed by the medical profession [6, 7]. One explanation for diagnostic difficulties is that lipoedema is a little-known disease, which can also be confused diagnostically with other conditions that present with limb enlargement such as lymphoedema or gynoid obesity [3, 8].

In chronic lymphoedema there can be a significant fat composition which contributes to leg swelling [9] and secondary lymphoedema may complicate lipoedema, so called lipolymphoedema. Another distinguishing feature of lymphoedema is a high rate of cellulitis due to immune dysfunction from

impaired lymphatic drainage [10]. This again contrasts with an absence of cellulitis reports in lipoedema patients (unless they have developed secondary lymphoedema).

Lipoedema is not always simple to differentiate from obesity. Gynoid fat distribution can look identical to lipoedema but is less painful and in theory responsive to calorie restriction. Obesity may be assessed by calculating body mass index (BMI), defined as the weight in kilograms divided by the square of the height in meters (kg/m^2). The WHO categorises a BMI over 25 kg/m^2 as overweight, and a BMI over 30 kg/m^2 as obese [11]. Patients with lipoedema usually have elevated BMIs because of big heavy legs but whilst obesity will respond to restricted dietary intake, the abnormal fat of lipoedema is far less responsive, leading to a wasted upper body but a lower body that stubbornly remains disproportionately enlarged from the waist to the ankles. The abnormal response to weight-reducing diets would argue against a form of obesity. However, later in life, lipoedema is often complicated by obesity, in which case, historical symptoms of disproportionately big legs but small upper trunk are key to the diagnosis. Interestingly, patients with lipoedema display a less severe cardiovascular profile and have a normal lipid profile than those of equivalent BMI without lipoedema [12-14]. The gynoid profile of lipoedema may even protect against diabetes [12, 15].

The diagnosis of lipoedema can be difficult to make if lymphoedema and/or obesity co-exist. One of the major problems with the diagnosis of lipoedema is the lack of a confirmatory test. The exploration of ultrasound in lipoedema proves promising [16, 17]; however, it is not yet an established gold standard.

Exactly what causes lipoedema is not known. Family history has been reported in lipoedema patients suggesting a familial origin of the disease [5, 18] but many cases also appear to be sporadic. Genes or loci associated with the condition are still in need of identification. As a single gene (monogenic) cause has not yet been identified, we therefore believe that the genetic architecture of the disease is more complex with a mix of genetic and environmental risk factors contributing. To investigate this hypothesis, we have conducted a Genome Wide Association Study (GWAS) to investigate genetic

associations with the lipoedema trait. Obtaining meaningful genetic results rely on studying as homogenous a group of phenotypes as possible. Therefore, the cohort of patients were selected on strict clinical criteria. As reduced quality of life has been reported in women with lipoedema [4, 19], the recruits were also subjected to self-administered health related quality of life (HRQoL) assessment as the items that are objectively measured in the HRQoL assessment can assist in the diagnostic criteria. Identifying the possible genetic causes could help to better define lipoedema, facilitate the development of a diagnostic test, and could lead to possible treatments.

Materials and Methods

Case ascertainment

Patient recruitment occurred through referrals to the two UK specialist clinics at St George's University Hospital NHS Trust and the University Hospitals of Derby and Burton NHS Trust. Further recruitment was encouraged through advertisement to the members of 'LipoedemaUK' local patient support group meetings and conferences. The patients were seen by clinicians or a research nurse with a specialist interest in lymphoedema and lipoedema (authors GB, KG, KR, PSM, RE and VK). Ethical approval was obtained from the local Health Research Authority (REC reference number: 16/LO/0005). Individuals were invited to participate if they matched the major inclusion criteria and written informed consent was obtained from all participants. Methodological details regarding inclusion criteria and the data obtained through interview and clinical assessment are reported in Table 1 and the Supplementary Methods.

Table 1. Summary of inclusion criteria.

Inclusion criteria
Female
Age of onset (<35y)
BMI ≤ 40 kg/m ²
Waist-hip ratio (WHR) ≤ 0.85
No or minimal central (android) obesity
Bilateral and symmetrical fat hypertrophy on lower limbs
Spared feet
Persistent enlargement (with no significant effect from overnight elevation)
White British ethnicity (only for the GWAS)

Health related quality of life assessment

Patients were invited to complete the 36 items of the General Health Questionnaire Short Form (SF-36 Health Survey) by themselves at the time of their appointment. Participation in this study was voluntary and no incentives were offered. The SF-36 measures eight domains related to 'Physical Functioning', 'Physical Role Limitations', 'Emotional Role Limitations', 'Vitality' (or energy), 'Emotional and Mental Wellbeing', 'Social Functioning', 'Bodily Pain', and 'General Health'. If more than 25% of the questionnaire was incomplete, it was excluded from analysis. The Likert like scores were transformed to range from zero to 100 and the methods for computing the scores followed reported guidelines [20]. Scores from the eight SF-36 domains were correlated with clinical records such as participant BMI, age of onset of lipoedema and waist-hip ratio (WHR). Correlations between the SF-36 domain scores, and between demographic variables were also computed.

Genotyping of the discovery cohort

Recruits who identified as being of white British ancestry were invited to participate in the genotyping arm of the study. 148 consented and peripheral blood was obtained, DNA extracted, and genotyped in two batches by Cambridge Genomic Services using Illumina Infinium_CoreExome-24_v1-2 single nucleotide polymorphism (SNP) chip and by UCL Genomics facilities using the Infinium_Core-24_v1-2-

a1 SNP chip. To avoid batch effect generated by genotyping the lipoedema samples in two slightly different SNP arrays, 22 samples were genotyped in both batches and SNPs showing inconsistency (n=4) between the two arrays were removed. 5,849 female samples of white British ethnicity enrolled in the Understanding Society UK study [21] and genotyped using HumanCoreExome-12_v1.0 were used as controls (European Genome-phenome Archive ID: EGAD00010000890).

Replication cohort

For the replication study, whole genome sequencing data from the Genomics England (GEL) 100,000 Genomes Project Rare Diseases program (main-programme_v11) was used [22]. In the Cardiovascular Genomics England Clinical Interpretation Partnership (GeCIP), 93 participants were identified with the label “Lipoedema” in the lymphatic disorder subdomain. To ensure there was no overlap between the discovery cohort and the replication cohort, GEL participants already included in the discovery cohort or participants related to individuals in the discovery cohort were excluded. GEL participants not marked as “Europeans” by the 100,000 Genomes Project inferred ancestry were also excluded, and so were individuals who had HPO terms indicating comorbidities unrelated to lipoedema, leaving us with 27 cases for the replication cohort. Unaffected females without a diagnosed condition, marked as “Europeans” and unrelated to each other and/or to the lipoedema cases were selected as the control group of the replication cohort (N=11,409).

Association Analyses and Meta-analysis

Discovery cohort and control genotyping data underwent thorough quality control before association analysis using PLINK (v1.90b6.21 & v2.00a3LM) [23]. Samples with either low calling rate (< 97%) or ± 3 SD deviation from the heterozygosity rate mean of the samples (N_{Cases}=4, N_{Controls}=85) were excluded from the analysis. Relatedness between all sample pairs in the cohort was inferred by calculating identity by descent. In sample-pairs with PI_HAT>0.05, the sample with the highest BMI and WHR (for cases) and/or lower genotyping calling rate was excluded (N_{Cases}=9, N_{Controls}=304). The cohort was merged with the CEU, CHB and YRI reference populations from HapMap study [24] and

genetically divergent ethnic outliers were excluded ($N_{\text{Cases}}=5$, $N_{\text{Controls}}=59$) after performing principal component analysis using GCTA package (v1.93.2beta) [25] leaving 130 cases and 5,401 controls in the discovery cohort. SNPs with minor allele frequency (MAF) <0.01 , missing call rate >0.05 , and Hardy-Weinberg equilibrium $\leq 1 \times 10^{-6}$ were excluded from the analysis.

SNP-based heritability association analysis was then calculated in the discovery cohort by using the restricted maximum likelihood (`--reml`) option in the GCTA package. Since the prevalence of lipoedema is still elusive the calculation was performed by using both a prevalence of 5% and 10%.

Association analysis was performed in the discovery cohort using PLINK 1.9 logistic regression. The distribution of the association P -Values was assessed using a Quantile-Quantile plot (Q-Q) plot. The 30 SNPs with the lowest P -values in 27 distinct loci were tested for association with lipoedema in the replication cohort using PLINK 1.9 logistic regression. Summary statistics from both studies were used to perform a meta-analysis for these 30 SNPs using METAL software [26]. The “SCHEME STDERR” approach was followed so the meta-analysis was performed on Odds Ratios (OR) and their standard errors. These SNPs were annotated using SNPnexus [27], while their impact on gene expression in different tissues was explored using expression quantitative trait loci (eQTL) information from the Genotype Tissue Expression (GTEx) Portal [28] using LDexpress Tool [29]. Gene Ontology (GO) [30] analyses were performed using DAVID Bioinformatics Resources [31]. Further SNP fine mapping was performed by using the ENCODE Candidate Cis-Regulatory Elements combined from all cell types [32] and Clustered interactions of GeneHancer regulatory elements and genes [33] databases using the UCSC Table Browser [34]. Scripts used for the analysis can be found on GitHub (https://github.com/digrigor/SGUL_UK_Lipoedema_GWAS).

Results

Patient selection criteria

Patient selection used clearly defined clinical criteria (Table 1, Supplementary Methods). These included painful excess adipose deposition from the hips to the ankles (Fig 1A-G), BMI ≤ 40 but no

excess upper body fat, waist-hip ratio (WHR) ≤ 0.85 , soft and “doughy” tissues, and sparing of the feet.

Women with proximal upper limb lipoedema (Fig 1G) were also included in the study.

Fig 1. Examples of recruited patients. (A-C) Three female patients with relatively mild lower limb lipoedema manifesting with excess adipose deposition from the hips to the ankles. The patients do not have obesity and their BMIs range from 23.7 (within the normal/healthy weight range) to 26.6 (overweight). Waist-hip ratios (WHR) for all three women are less than 0.75. (D) A female patient with lower limb lipoedema possessing the same clinical signs as patients in A-C. However, the additional finding of a well-defined lipoma is clearly visible on the right anterior thigh (arrow). (E-G) Two women with moderately severe lower limb lipoedema. Proximal upper limb lipoedema is noticeable in (G). Ankle braceleting is clearly present in both women, and no evidence of secondary lymphoedema or venous disease. Both women have an elevated BMI in the “obesity” range, but their WHRs are less than 0.75. There is a bruise on the left shin in (G) (arrow) that reportedly developed after minimal trauma to the area. (H-J) A female patient with four-limb lipoedema, mild lymphoedema of the lower legs and grade CEAP2 venous disease with telangiectasia and asymptomatic varicose veins. This patient was initially diagnosed with lower limb lymphoedema as a result of morbid obesity. Bariatric surgery was undertaken, and significant weight loss was achieved (~50kg). Her four-limb lipoedema had been masked by the obesity and only became apparent after significant weight loss revealed disproportionate fat deposition of the limbs. (K-M) This patient with severe lower limb lipoedema did not meet initial inclusion criteria as her BMI was 44 at the time of recruitment, despite a WHR of 0.78. However, she is a longstanding patient of the clinic with documentation of BMI <35 at time of first presentation.

Additional patients were included who might not have had a clear-cut diagnosis. One patient was initially diagnosed with lower limb lymphoedema as a result of morbid obesity. Bariatric surgery was undertaken, and significant weight loss was achieved (~50kg reduction). Her four-limb lipoedema had been masked by the obesity and only became apparent after the weight loss revealed disproportionate fat deposition of the limbs (Fig 1 H-J). Other patients presented with BMI > 40 at time of recruitment to the study (Fig 1K-M), but as they were longstanding patients of the clinic with documentation of BMI < 35 at time of presentation, they were included too. Although these recruits had increased waistline and android fat distribution, all still had a WHR ≤ 0.85 and the significantly elevated BMI reflects the progression of lipoedema over several years with increasing volumes of disproportionate (gynoid) adipose deposition of the lower limbs.

Patient summary characteristics

A total number of 200 women were recruited between September 2016 and March 2018 through face-to-face interview and clinical examination. The face-to-face interview included questions that are often self-reported by women with lipoedema such as the presence of pain or tenderness to the touch, noticeable easy bruising and disproportionate weight loss upon dieting. A summary of patient characteristics is documented in Table 2 and the full data are available in S1 Table.

Table 2. Summary characteristics of the 'UK Lipoedema' cohort. Observations from the clinical examination and information obtained through face-to-face interview at time of recruitment is included. A total of 200 individuals were recruited to the study. 'Missing data' indicates the number of individuals where values were not obtained.

	Mean $\pm$ SD	Range	Missing data
Age at evaluation (yrs)	47.0 $\pm$ 13.5	(18-81)	0

Age at evaluation classes (yrs)	N	%
18-25	12	6.0
26-35	25	12.5
36-50	80	40.0
51-65	65	32.5
>65	18	9.0

	Mean $\pm$ SD	Range	Missing data
Age at onset of lipoedema (yrs)*	16.8 $\pm$ 9.0	(6-60)	22
Start of puberty (yrs)*	12.5 $\pm$ 1.6	(9-17)	18
Disease duration (yrs)	29.2 $\pm$ 12.9	(1-62)	22
Height (m)	1.65 $\pm$ 0.07	(1.46-1.85)	5
Weight (kg)	90.4 $\pm$ 20.0	(47-160)	9
BMI	33.4 $\pm$ 7.2	(19.0-58.8)	8
Waist circumference (cm)	91.3 $\pm$ 13.4	(42-123)	38
Hip circumference (cm)	120.4 $\pm$ 14.3	(90-169)	37
Waist-hip ratio (WHR)	0.76 $\pm$ 0.07	(0.40-0.93)	38

BMI class	N	%
<25	21	10.8
25-29.9	48	25.0
30-34.9	48	25.0
35-39.9	42	21.9
40-49.9	30	15.6
$\geq$ 50	3	1.6

	%	(N/total)	Missing data
White British*	92.5	(185/200)	0
Family history*	58.2	(110/189)	11

*, self-reported, information obtained through interview; N, number of cases; SD, standard deviation; Total, total number of cases; yrs, years. Disease duration calculated as 'Age at evaluation' minus 'Age at onset of lipoedema'.

Table 2, continued

Oedema				
	Age class (yrs)	N with oedema	Total	%
	≤35	4	35	11.4
	35-60	35	126	27.8
	>60	14	35	40.0
	All oedema	53	196	27.0
		%	(N/total)	Missing data
	<i>Oedema of ankle (sometimes incl feet)</i>	51.1	(24/47)	6
	<i>Oedema of leg/lower limb</i>	38.3	(18/47)	6
	<i>Intermittent oedema*</i>	10.6	(5/47)	6
Venous problems[‡]				
		%	(N/total)	Missing data
	<i>CEAP ≥C3</i>	2.6	(5/190)	10
	<i>CEAP C2</i>	25.3	(48/190)	10
	<i>CEAP C1</i>	19.5	(37/190)	10
	<i>CEAP C0</i>	52.6	(100/190)	10
	<i>Venous problems and lymphoedema</i>	13.2	(25/190)	10
Other features				
		%	(N/total)	Missing data
	<i>Tender to touch and pain*</i>	71.0	(110/155)	45
	<i>Bruise easily*</i>	90.3	(139/154)	46
	<i>Hypermobility</i>	17.8	(33/185)	15
	<i>Pes planus</i>	22.2	(40/180)	20
	<i>Liposuction*</i>	6.2	(11/177)	23
	<i>Responsiveness to dieting*</i>			
	<i>Disproportional response</i>	86.7	(144/166)	34
	<i>No loss</i>	7.8	(13/166)	34
	<i>Equal loss all over</i>	5.4	(9/166)	34

*, self-reported, information obtained through interview; N, number of cases; SD, standard deviation; Total, total number of cases; yrs, years. ‡We were not specifically assessing for varicose veins; no venous duplex was carried out, so hidden (deeper) varicose veins have not been recorded. CEAP, Clinical Etiological Anatomical Pathophysiological classification; CEAP C0, no visible or palpable varicose veins; CEAP C1, mild superficial venous problems such as spider, reticular or thread veins (telangiectatic); CEAP C2, uncomplicated varicose veins such as enlarged, prominent veins; CEAP >C3, varicose veins with symptoms.

At recruitment, the majority stated they were white British (92.5%), and the mean age was 47 years (SD±13.5; range 18y-81y) (Table 2). On average, the individuals reported to have been affected by lipoedema for 29.2 years (SD±12.9) with an age of onset at 16.8 years old (SD±9.0).

Clinical examination showed the mean weight among the lipoedema cases was 90.4kg (SD±20.0), mean height 1.65m (SD±.07) and the mean BMI was 33.4 (SD±7.2) (Table 2). The high BMI was not due to high levels of android fat as the average waist circumference was 91.3cm (SD±13.4), and hip circumference was 120.4cm (SD±14.3), thus the average calculated waist-hip ratio (WHR) was 0.76 (SD±0.07). This is less than the WHO recommended WHR of 0.85 for women, indicating that central obesity was not the cause of elevated BMI values [35]. Distribution of BMI, WHR and waist circumference among the cases are shown in S1 Fig.

Patients were examined for hypermobility or joint laxity of the elbows, knees, small joints of the hands and the back during the clinical assessment because there are anecdotal reports of increased hypermobility with lipoedema. 17.8% (33 recruits out of 185) were hypermobile (Table 2). Individuals were also examined for the presence of pitting oedema as part of the clinical assessment. In 53 (27%) recruits, mild pitting oedema was observed. The majority of oedema was observed in the older age groups (49/53 individuals with oedema were >35y). In most cases the oedema was either intermittent or confined to the ankles (61.7%). The underlying reason for the oedema was not investigated.

The face-to-face interview revealed that 58.2% (110/189) self-reported to have a family history of lipoedema (Table 2). Easy bruising, seen as one of the parameters to assess lipoedema, was self-reported in 90.3% individuals. 71% reported their limbs to be tender to the touch. On examination, 47.4% had clinically evident venous abnormalities, mostly mild superficial telangiectasia or uncomplicated varicose veins consistent with CEAP C1 and C2 disease (Table 2, Fig 1H-M).

When asked about the effect of dieting, 86.7% of recruits reported a disproportional weight loss where they found it easier/quicker to lose weight from the torso compared to the limbs (Table 2). Only 7.8% reported no loss of fat at all from the limbs with dieting/weight loss. 6.2% of recruits had undergone liposuction and one individual had undergone bariatric surgery. The bariatric surgery had led to 50kg weight loss, but unfortunately this accentuated her disproportionate body shape as more weight was lost from the torso compared to the limbs unmasking the lipoedema phenotype (Fig 1H-I).

Health related quality of life assessment

Physical, social and mental aspects of health were evaluated by using the validated and widely used self-reported Short Form-36 Quality of Life Questionnaire (SF-36). 135 women of the 200 recruited completed enough domains of the questionnaire to be included for analysis (S2 Table). The scores across the eight domains ranged from 40.2 – 64.7 (out of 100; with 100 indicating better health status) (Table 3). Multiple significant ($P < 0.05$) correlations were found between SF-36 scores and clinical variables (S3 Table). The strength of most of the relationships was weak-moderate as the absolute value of the correlation coefficient, r , was < 0.7 . A few domains did show a strong relationship with the bodily pain domain, so that those experiencing lots of pain in the bodily pain domain also would report worse general health ($r = 0.70$) and physical functioning ($r = 0.78$) (S3 Table). The social functioning domain was also found to correlate strongly to the emotional and mental wellbeing domain ($r = 0.72$).

Table 3. Outcome of evaluation of health status in 135 lipoedema cases who completed the SF-36 Quality of Life Questionnaire.

Dimension	Mean	Std. Deviation
Physical functioning	61.1	28.0
Role limitations physical	58.9	42.9
Role limitations emotional	57.9	42.9
Vitality	40.2	23.9
Emotional/mental Wellbeing	60.1	19.9
Social functioning	64.7	27.1
Bodily pain	57.1	27.1
General health	49.5	21.2

The mean score and the standard deviation of all dimensions is given. The individual 36 questions are scored with a Likert-type scale and the eight domains of health are computed means to a 0 -100 scale. Higher scores indicate better health status.

Genome-Wide Association Analysis

Of the 200 recruited lipoedema cases, 130 white British were included in a GWAS discovery cohort (indicated in S1 Table) with 5,531 ethnically matched female controls from the Understanding Society the UK Household Longitudinal Study cohort. The replication cohort consisted of 27 ethnically matched lipoedema cases (S4 Table) and 11,409 female controls enrolled in the 100,000 Genomes Project Rare Diseases Program v11. After quality control implementation, 233,441 SNPs were tested for association with the lipoedema trait in the discovery cohort using logistic regression analysis. The 30 SNPs showing the greatest association with lipoedema were selected for replication in the independent cohort, where genotyping was done by Whole Genome Sequencing, using logistic regression analysis. A meta-analysis was then performed to pool the per-SNP effect sizes from the discovery and replication studies.

To ensure there was no systematic bias in the discovery study arising from population stratification, a principal component analysis was performed with the HapMap population reference panel samples, revealing that after the quality-control steps there are no ethnic outliers left in the study, as both lipoedema cases and controls cluster together with the Central European HapMap population (Fig 2A). This is further highlighted by the absence of genomic inflation ($\lambda_{gc} = 1.004$) on the QQ plot of the

observed P values (Fig 2B). To understand the proportion of genetic variance influencing the lipoedema phenotype in our cohort, SNP-based heritability (h^2_{SNP}) in the discovery cohort was estimated and found to be 0.50 (SE = 0.52, P = 0.17) and 0.62 (SE = 0.65, P = 0.17) when the prevalence of lipoedema in the population was set to 5% and 10%, respectively. However, there is a lack of statistical significance in this estimation due to the limited sample size.

Figure 2. Results of the ‘UK Lipoedema’ discovery cohort Genome-Wide Association Study (GWAS) and meta-analysis. (A) Plot of the first two principal components from the PCA performed on the GWAS (lipoedema cases and controls) samples and the HapMap individuals. (B) Quantile–Quantile plot of GWAS samples showing no genomic inflation. (C) Manhattan plot of the genome-wide P -values (in $-\log_{10}$ scale) of association with lipoedema in the discovery cohort. The association was tested using logistic regression analysis. The highlighted SNPs (dots with black outline) were tested in the replication cohort and have $P_{meta} < 5 \times 10^{-4}$ and same direction of effect for both studies. (D) Forest plot of the chromosome 13 rs1409440 SNP meta-analysis pooled odds ratios and 95% confidence intervals. (E) Regional plot of the top three SNPs (rs1409440, rs7994616, rs11616618) from the meta-analysis in one distinct genomic locus on chromosome 13 near the *LHFPL6* gene.

The association analysis in the discovery cohort revealed multiple suggestive genomic loci associated with lipoedema. Although there were no SNPs passing the genome-wide significance threshold ($P < 5 \times 10^{-8}$), 30 SNPs with $P < 1 \times 10^{-4}$ were identified (Fig 2C, S5 Table). Nine of these SNPs (in seven distinct loci) were supported in the replication cohort with $P_{meta} < 1 \times 10^{-4}$ and same direction of effect for both analyses (Table 4).

Table 4. List of the meta-analysis replicated variants.

Chr	Pos (hg38)	ID	Nearest Gene(s)	Annotation	Major/Minor	Discovery			Replication			Meta Analysis	
						AF Ca/Co	OR	P-Value	AF Ca/Co	OR	P-Value	OR	P-Value
13	39111430	rs1409440	<i>NHLRC3;NXT1P1</i>	Downstream; Upstream	T/C	0.17/0.09	2.03	2.12E-05	0.17/0.09	1.92	7.27E-02	2.01	3.98E-06
13	39134958	rs7994616	<i>NHLRC3;NXT1P1</i>	Downstream; Upstream	T/C	0.17/0.09	2.03	2.15E-05	0.17/0.09	1.92	7.28E-02	2.01	4.00E-06
13	39140014	rs11616618	<i>NHLRC3;NXT1P1</i>	Downstream; Upstream	G/A	0.17/0.09	2.03	2.32E-05	0.17/0.09	1.91	7.48E-02	2.00	4.48E-06
4	165159085	rs9308098	<i>TMEM192</i>	intronic	T/C	0.21/0.12	1.87	2.79E-05	0.17/0.13	1.38	3.81E-01	1.78	2.50E-05
17	14460349	rs10521271	<i>AC022816.2;RPS18P12</i>	Downstream; Upstream	C/T	0.04/0.01	3.63	1.24E-04	0.04/0.01	3.33	9.86E-02	3.57	2.96E-05
10	38680369	rs11511253	<i>SLC9B1P3</i>	intronic	G/A	0.32/0.21	1.70	1.08E-04	0.30/0.22	1.53	1.61E-01	1.67	4.07E-05
4	9699920	rs4554078	<i>FAM86MP</i>	Downstream	G/A	0.05/0.02	3.14	7.44E-05	0.07/0.04	1.90	2.14E-01	2.79	4.82E-05
7	99173839	rs10499948	<i>KPNA7</i>	intronic	A/G	0.07/0.03	2.75	3.40E-05	0.04/0.03	1.22	7.80E-01	2.53	5.91E-05
2	145667963	rs16825349	<i>AC079163.1;AC079248.1</i>	Downstream; Upstream	A/G	0.28/0.18	1.74	9.32E-05	0.24/0.19	1.37	3.20E-01	1.66	7.11E-05

List of the meta-analysis variants ($P_{meta} < 5 \times 10^{-4}$ and same direction of effect for both studies) associated with lipoedema in discovery and replication studies. The variants have been annotated to their nearest genes. Allele Frequencies (AF), Odds Ratios (OR) and *P*-values are shown for both studies and meta-analysis. The variants have been sorted in ascending meta-analysis *P*-value order.

According to the meta-analysis, the top three lipoedema-associated SNPs (rs1409440, rs7994616, and rs11616618; $OR_{meta} \approx 2.01$, $P_{meta} \approx 4 \times 10^{-6}$, Fig 2D) are in a block of linkage disequilibrium (LD) on chromosome 13. The block, which is ~40kb with $r^2 > 0.8$, is near the *FREM2*, *STOML3*, *PROSER1*, *NHLRC3*, and *LHFPL6* genes (Fig 2E). When mapping these non-coding SNPs to regulatory elements in the genome all three are located in an *LHFPL6* interaction region according to the GeneHancer database, while based on the ENCODE project classifications, rs1409440 is specifically located in a distal enhancer-like signature locus upstream of *LHFPL6* (S6 Table). Localization of this LD block in regulatory elements of *LHFPL6* suggests it is a regulator of the gene's expression. This is highlighted by the direct significant association ($P < 5 \times 10^{-6}$) between several LD buddies ($r^2 > 0.6$) of the three SNPs with *LHFPL6* expression in many tissues, for example, in skin ('sun exposed lower leg'), as shown by the expression quantitative trait loci (eQTLs) analysis (S7 Table).

To explore whether the presence of these three variants upstream of *LHFPL6* affects the clinical characteristics of the carriers, the phenotypic characteristics of the group of patients carrying all three SNPs ($N = 45$: $N_{Discovery} = 38$, $N_{Replication} = 7$) were compared against those of non-carriers in both discovery and replication cohorts. The results showed that lipoedema patients carrying the variants upstream of *LHFPL6* were significantly more likely to report a direct maternal relative (mother, daughter, sister) with lipoedema symptoms (chi-squared test: χ^2 (1, $N = 157$) = 10.03, $P = 0.002$), highlighting the putative contribution of this locus, upstream to *LHFPL6*, to the genetic aspect of the disease.

Next, we explored the eQTL signals of the other SNPs (Table 4), to investigate links with the lipoedema phenotype. The SNP rs11511253 ($P_{meta} = 4.07 \times 10^{-5}$, $OR_{meta} = 1.67$) is associated either directly or through its LD buddies with the expression of the genes (*ZNF25* and *ZNF33A*), pseudogenes (*CICP9*, *HSD17B7P2*, *SEPT7P9*) and long non-coding RNAs (*RP11-258F22.1/lnc-ZNF248-1*; *RP11-291L22.9/lnc-ZNF37A-4*; *RP11-508N22.12/lnc-ZNF33A-8*) in, among others, lipoedema-related tissues like subcutaneous adipose tissue, and oestrogen-producing tissues such as adrenal gland, hypothalamus, breast, ovary and pituitary (S7

Table). rs9308098 ($P_{meta} = 2.50 \times 10^{-5}$, $OR_{meta}=1.79$) is associated with *CPE* and *KLHL2* gene expression in adrenal gland tissue (S7 Table).

Further investigation of links between the top SNPs and the lipoedema phenotype was undertaken. A gene ontology enrichment analysis was performed using DAVID on the genes associated with the SNPs either directly (SNPs located in the gene, $n=4$ from Table 4) or through eQTLs ($n=29$ from S7 Table) (as listed in S8 Table). The analysis showed that *CYP3A4* and *CYP3A5*, which are both associated with replicated SNP rs10499948 ($P_{meta} = 5.91 \times 10^{-5}$, $OR_{meta} = 2.53$; Table 4), participate in specific biological processes including lipid hydroxylation and aromatase activity which are probably relevant to lipoedema (S9 Table).

Discussion

Lipoedema is a clinical diagnosis in urgent need of an understanding of mechanism and treatment. No good biomarkers exist, and the disease manifestations show phenotypic overlap with other disorders, hampering the clinical diagnosis. Here we report the first comprehensive collection of lipoedema cases recruited from a white British population, with the aim of conducting a GWAS to explore a possible polygenic architecture. Through careful phenotyping we have been highly selective in recruitment of cases, taking care to exclude those with generalized obesity where lipoedema is difficult to diagnose.

Approximately half the recruited women reported a family history of large legs, and this is consistent with the estimated SNP-based heritability of 50-60% calculated in the discovery cohort, indicating a strong genetic link to lipoedema. However, larger lipoedema cohorts are needed to validate this estimation. Strong association of autosomal dominant inheritance with sex limitation has been observed within affected family members with lipoedema [3]. Despite a small cohort size, we believe the careful phenotyping has led to the identification of some putative regions of genetic association. The top three SNPs in our analysis, rs1409440, rs7994616 and rs11616618, were located on chromosome 13 in a block

of linkage disequilibrium (LD) close to the *LHFPL6* gene, while fine-mapping analysis results showed that all three SNPs are associated with *LHFPL6* gene expression. The eQTLs supporting this association were identified in lower leg skin tissue, amongst others. The *LHFP* (*LHFPL6*) gene is a member of the lipoma HMGIC (High-mobility group protein isoform C) fusion partner gene family and it is localized to chromosome 13q. It has been associated with higher levels of polyunsaturated fats in adipose tissues in thigh tissue in chicken [36] and it has been linked to a translocation-associated lipoma [37], making it an interesting gene to explore. Petit *et al.* described an acquired cytogenetic translocation in a lipoma with breakpoints at 12q13-15 and 13q12 resulting in a fusion transcript between the genes *HMGIC* and *LHFP* [37]. Further cytogenetic analysis of various types of benign and malignant lipomas detected structural (balanced and unbalanced) rearrangements of or monosomy (clonal loss) for chromosome 13q and the authors speculated if haplo-insufficiency was the pathogenetic mechanism [38].

Lipomas are common soft tissue tumours identified as a ‘benign neoplasm of mature adipocytes’ [39]. They are characterized by non-symmetrical fat accumulations which are soft, fatty lumps present in the subcutaneous layer. They have been reported in association with lipoedema [1, 40], and in our clinics some lipoedema patients have reported the presence of lipomas (see Fig 1D), but as they are not considered diagnostic of lipoedema our data collection did not consistently record this. In contrast, lipomas are well described in Dercum’s disease or “painful fat syndrome” [41] which lies within the spectrum of lipoedema. The localized deposits of fatty tissue around the knees seen in many individuals with lipoedema might represent lipoma-like adipose tissue [42, 43] and it has been suggested that lipoedema and lipomas may be associated as both can present with excessive adipose tissue [40]. The GWAS participants from our cohort carrying the SNPs associated with *LHFPL6* were significantly more likely to report direct maternal family history compared to the non-carriers. However, how *LHFPL6* is linked to excessive adipose tissue in lipoedema is not known. Although further investigation is needed to

prove causality in this correlation, this finding is consistent with a genetic association between this locus and the onset of familial lipoedema.

Another finding from our enrichment analysis worth mentioning is of the GWAS results using eQTL data which revealed an association to the *CPE* gene. This gene encodes the Carboxypeptidase E protein which is involved in the biosynthesis of many neuropeptides and peptide hormones, e.g. estrogen. A *CPE* point mutation has been shown to cause loss of CPE activity leading to late onset obesity in homozygous mice [44]. The obesity was not characteristic of other obese mutant mice models and is not thought to be caused by increased food intake, but as a result of defective nutrient processing. Of other interesting associations, the SNP, rs11511253, which associated with the expression of the *ZNF25* and *ZNF33A* genes and some long non-coding RNAs and pseudogenes in adipose tissue and various oestrogen expressing tissues would be interesting to explore further. Likewise, the two genes *CYP3A4* and *CYP3A5* and their involvement in lipid hydroxylation and aromatase (also known as oestrogen synthetase) activity, as identified through the pathway analysis, could elucidate some of the underlying disease mechanisms, for example, if and how oestrogen is related to the lipoedema phenotype.

Despite the strict selection criteria limiting numbers of recruits, the “UK Lipoedema” cohort is typical of other lipoedema cases described in the literature. The recruited lipoedema patients are strikingly similar to that of Dudek and colleagues, who reported similar low WHR ratios (average value = 0.78), self-reported high levels of easy bruising (91%), tenderness/pain (83%) and disproportional weight loss (87%) [14]. The age of onset was mainly reported as pubertal. The majority of women (86.7%) in our cohort reported disproportional weight loss upon dieting. However, it is important to also acknowledge these women reported that fat loss was achievable from affected limbs. Why so many women with lipoedema suffer with obesity is not yet understood – is it “cause and effect”, or are there more complicated genetic reasons behind it? Clearly there is an urgent need for research into the possible association between lipoedema

and obesity, but until then it is important to ensure that women with lipoedema access successful weight management strategies to ensure weight gain and progression of lipoedema are avoided.

Chronic fatigue, psychosocial and poor body image issues are recognized comorbidities with lipoedema. Many lipoedema patients will have been dismissed by their doctors at some point and told to manage their weight by dieting or lifestyle changes. Diets and physical exercise are reported to lead to disproportionate loss of weight from the upper half of the body in patients with lipoedema, accentuating the disproportional figure. The disproportionate body shape in females can cause negative body image and “body shaming” criticism from friends, family, and health care professionals. As an impact of overall psychological well-being this could lead to patient experiences of distress, anxiety, depression, eating disorders and isolation [2, 4]. The SF-36 questionnaire confirmed that quality of life was reduced in all eight domains evaluated. This is comparable to other studies of lipoedema patients using either the SF-36 or similar investigative tools [4, 19, 45]. The mean scores across eight domains show more consistency with chronic neuropathic pain patients than obesity patients (S2 Fig.) [46, 47] suggesting similarities with individuals that have a chronic condition.

The main limitation of this study was the small numbers. We tried in particular to use BMI < 30 and WHR < 0.80 as inclusion criteria, but this resulted in too small a sample size. Thus, criteria had to be loosened to include cases with BMI $\leq$ 40 and WHR $\leq$ 0.85. This can only be recommended if there is sufficient medical history for the clinician to confirm the diagnosis. Despite being less conservative in inclusion, we still had a relatively small sample size, which limited our statistical power in the GWAS, but we believe the homogeneity of the cohort helped to enrich the dataset. Another limitation related to the samples obtained from the ‘Understanding Society UK study’ (controls) and GEL (cases and controls), which both lack information on waist-hip ratio and BMI. Such data would have been extremely valuable for excluding any potential lipoedema cases from the controls and to have understood if the cases from the GEL replication cohort would have fulfilled the lipoedema inclusion criteria.

In conclusion, we have described a tightly phenotyped lipoedema cohort from a UK population. Based on genetic analysis, we identified suggestive SNPs linked with the disease, notably at chr13q13.3 near the *LHFPL6* gene. The meta-analysis of the discovery and replication cohorts also revealed six other distinct genetic loci putatively associated with the disease. These results show some interesting connections relevant to the disease phenotype. However, replication of the GWAS in different populations is needed. From our findings, we cannot tell the true driver of disease and follow-up studies investigating the associated loci/genes are needed. In time this could enable a better understanding of the underlying genetic causes of lipoedema and its disease mechanism and perhaps even fat deposition and homeostasis in general.

Acknowledgement

The authors thank all participants for volunteering their time for this study. We would also like to thank 'LipoedemaUK' for facilitating recruitment through their members. This research was made possible through access to the data and findings generated by the 100,000 Genomes Project and Understanding Society. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100,000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support. Understanding Society is an initiative funded by the Economic and Social Research Council and various Government Departments, with scientific leadership by the Institute for Social and Economic Research, University of Essex, and survey delivery by NatCen Social Research and Kantar Public. The research data are distributed by the UK Data Service. We also extend our thanks to members of the St George's

University of London (SGUL) Lymphovascular Research Team for invaluable discussions and feedback on our work and to the following members of the Lipoedema consortium: Dr Yann Klimentidis, University of Arizona; Prof Natasha Harvey and Dr Hamish Scott, University of South Australia.

References

1. Fife CE, Maus EA, Carter MJ. Lipedema: a frequently misdiagnosed and misunderstood fatty deposition syndrome. *Adv Skin Wound Care*. 2010;23(2):81-92; quiz 3-4. Epub 2010/01/21. doi: 10.1097/01.asw.0000363503.92360.91. PubMed PMID: 20087075.
2. Buck DW, 2nd, Herbst KL. Lipedema: A Relatively Common Disease with Extremely Common Misconceptions. *Plast Reconstr Surg Glob Open*. 2016;4(9):e1043. Epub 2016/10/21. doi: 10.1097/gox.0000000000001043. PubMed PMID: 27757353; PubMed Central PMCID: PMC5055019.
3. Child AH, Gordon KD, Sharpe P, Brice G, Ostergaard P, Jeffery S, et al. Lipedema: An Inherited Condition. *American Journal of Medical Genetics Part A*. 2010;152A(4):970-6. doi: 10.1002/ajmg.a.33313. PubMed PMID: WOS:000276754000027.
4. Dudek JE, Białaszek W, Ostaszewski P, Smidt T. Depression and appearance-related distress in functioning with lipedema. *Psychol Health Med*. 2018;23(7):846-53. Epub 2018/04/05. doi: 10.1080/13548506.2018.1459750. PubMed PMID: 29614880.
5. Wold LE, Hines EA, Jr., Allen EV. Lipedema of the legs; a syndrome characterized by fat legs and edema. *Ann Intern Med*. 1951;34(5):1243-50. Epub 1951/05/01. doi: 10.7326/0003-4819-34-5-1243. PubMed PMID: 14830102.
6. Tiwari A, Myint F, Hamilton G. Management of lower limb lymphoedema in the United Kingdom. *Eur J Vasc Endovasc Surg*. 2006;31(3):311-5. Epub 2005/12/06. doi: 10.1016/j.ejvs.2005.09.017. PubMed PMID: 16324854.
7. Caruana M. Lipedema: A Commonly Misdiagnosed Fat Disorder. *Plastic surgical nursing : official journal of the American Society of Plastic and Reconstructive Surgical Nurses*. 2020;40(2). doi: 10.1097/PSN.0000000000000316. PubMed PMID: 32459759.

8. Okhovat JP, Alavi A. Lipedema: A Review of the Literature. *Int J Low Extrem Wounds*. 2015;14(3):262-7. Epub 2014/10/19. doi: 10.1177/1534734614554284. PubMed PMID: 25326446.
9. Borri M, Gordon KD, Hughes JC, Scurr ED, Koh DM, Leach MO, et al. Magnetic Resonance Imaging–Based Assessment of Breast Cancer–Related Lymphoedema Tissue Composition. *Invest Radiol*. 522017. p. 554-61.
10. Mortimer PS, Rockson SG. New developments in clinical aspects of lymphatic disease. *Journal of Clinical Investigation*. 2014;124(3):915-21. doi: 10.1172/jci71608. PubMed PMID: WOS:000332347700006.
11. WHO. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. *World Health Organ Tech Rep Ser*. 1995;854:1-452. Epub 1995/01/01. PubMed PMID: 8594834.
12. Torre YS, Wadea R, Rosas V, Herbst KL. Lipedema: friend and foe. *Horm Mol Biol Clin Investig*. 2018;33(1). Epub 2018/03/10. doi: 10.1515/hmbci-2017-0076. PubMed PMID: 29522416; PubMed Central PMCID: PMCPMC5935449.
13. Wollina U. Lipedema-An update. *Dermatol Ther*. 2019;32(2):e12805. Epub 2018/12/20. doi: 10.1111/dth.12805. PubMed PMID: 30565362.
14. Dudek JE, Białaszek W, Gabriel M. Quality of life, its factors, and sociodemographic characteristics of Polish women with lipedema. *BMC Womens Health*. 2021;21(1):27. Epub 2021/01/16. doi: 10.1186/s12905-021-01174-y. PubMed PMID: 33446179; PubMed Central PMCID: PMCPMC7809838.
15. Pinnick KE, Nicholson G, Manolopoulos KN, McQuaid SE, Valet P, Frayn KN, et al. Distinct developmental profile of lower-body adipose tissue defines resistance against obesity-associated metabolic complications. *Diabetes*. 2014;63(11):3785-97. Epub 2014/06/21. doi: 10.2337/db14-0385. PubMed PMID: 24947352.

16. Iker E, Mayfield CK, Gould DJ, Patel KM. Characterizing Lower Extremity Lymphedema and Lipedema with Cutaneous Ultrasonography and an Objective Computer-Assisted Measurement of Dermal Echogenicity. *Lymphat Res Biol*. 2019;17(5):525-30. Epub 2019/01/08. doi: 10.1089/lrb.2017.0090. PubMed PMID: 30615553.
17. Marshall M, Schwahn-Schreiber C. Prevalence of lipoedema in professional women in Germany. (Lipoedema-3-study). *Phlebologie*. 2011;40:127-34.
18. Forner-Cordero I, Szolnoky G, Forner-Cordero A, Kemény L. Lipedema: an overview of its clinical manifestations, diagnosis and treatment of the disproportional fatty deposition syndrome - systematic review. *Clin Obes*. 2012;2(3-4):86-95. Epub 2012/06/01. doi: 10.1111/j.1758-8111.2012.00045.x. PubMed PMID: 25586162.
19. Romeijn JRM, de Rooij MJM, Janssen L, Martens H. Exploration of Patient Characteristics and Quality of Life in Patients with Lipoedema Using a Survey. *Dermatol Ther (Heidelb)*. 2018;8(2):303-11. Epub 2018/05/12. doi: 10.1007/s13555-018-0241-6. PubMed PMID: 29748843; PubMed Central PMCID: PMC6002318.
20. Ware J, Snow K, Kosinski M, Gandek B. SF-36 Health Survey: Manual and interpretation guide: The Health Institute, New England Medical Centre, Boston, Mass.; 1993.
21. University of Essex. Institute for Social and Economic Research NSR. Understanding Society: Waves 2-3 Nurse Health Assessment, 2010-2012 [data collection]. 3rd Edition. UK Data Service. SN: 7251. 2014.
22. Caulfield M, Davies J, Dennys M, Elbahy L, Fowler T, Hill Sea. The National Genomics Research and Healthcare Knowledgebase. 2017.

23. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience*. 2015;4:7. Epub 2015/02/28. doi: 10.1186/s13742-015-0047-8. PubMed PMID: 25722852; PubMed Central PMCID: PMC4342193.
24. Consortium. IH. The International HapMap Project. *Nature*. 2003;426(6968):789-96. Epub 2003/12/20. doi: 10.1038/nature02168. PubMed PMID: 14685227.
25. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. *Am J Hum Genet*. 2011;88(1):76-82. Epub 2010/12/21. doi: 10.1016/j.ajhg.2010.11.011. PubMed PMID: 21167468; PubMed Central PMCID: PMC3014363.
26. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics*. 2010;26(17):2190-1. Epub 2010/07/10. doi: 10.1093/bioinformatics/btq340. PubMed PMID: 20616382; PubMed Central PMCID: PMC2922887.
27. Oscanoa J, Sivapalan L, Gadaleta E, Dayem Ullah AZ, Lemoine NR, Chelala C. SNPnexus: a web server for functional annotation of human genome sequence variation (2020 update). *Nucleic Acids Res*. 2020;48(W1):W185-w92. Epub 2020/06/05. doi: 10.1093/nar/gkaa420. PubMed PMID: 32496546; PubMed Central PMCID: PMC7319579.
28. Consortium G. The Genotype-Tissue Expression (GTEx) project. *Nat Genet*. 2013;45(6):580-5. Epub 2013/05/30. doi: 10.1038/ng.2653. PubMed PMID: 23715323; PubMed Central PMCID: PMC4010069.
29. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. *Bioinformatics*. 2015;31(21):3555-7. Epub 2015/07/04. doi: 10.1093/bioinformatics/btv402. PubMed PMID: 26139635; PubMed Central PMCID: PMC4626747.

30. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet.* 2000;25(1):25-9. Epub 2000/05/10. doi: 10.1038/75556. PubMed PMID: 10802651; PubMed Central PMCID: PMCPMC3037419.
31. Huang DW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, et al. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. *Nucleic Acids Res.* 2007;35(Web Server issue):W169-75. Epub 2007/06/20. doi: 10.1093/nar/gkm415. PubMed PMID: 17576678; PubMed Central PMCID: PMCPMC1933169.
32. Moore JE, Purcaro MJ, Pratt HE, Epstein CB, Shores N, Adrian J, et al. Expanded encyclopaedias of DNA elements in the human and mouse genomes. *Nature.* 2020;583(7818):699-710. Epub 2020/07/31. doi: 10.1038/s41586-020-2493-4. PubMed PMID: 32728249; PubMed Central PMCID: PMCPMC7410828.
33. Fishilevich S, Nudel R, Rappaport N, Hadar R, Plaschkes I, Iny Stein T, et al. GeneHancer: genome-wide integration of enhancers and target genes in GeneCards. *Database (Oxford).* 2017;2017. Epub 2017/06/13. doi: 10.1093/database/bax028. PubMed PMID: 28605766; PubMed Central PMCID: PMCPMC5467550.
34. Karolchik D, Hinrichs AS, Furey TS, Roskin KM, Sugnet CW, Haussler D, et al. The UCSC Table Browser data retrieval tool. *Nucleic Acids Res.* 2004;32(Database issue):D493-6. Epub 2003/12/19. doi: 10.1093/nar/gkh103. PubMed PMID: 14681465; PubMed Central PMCID: PMCPMC308837.
35. WHO. Waist circumference and waist-hip ratio : report of a WHO expert consultation, Geneva, 8-11 December 2008: World Health Organization; 2011.
36. Yang S, Wang Y, Wang L, Shi Z, Ou X, Wu D, et al. RNA-Seq reveals differentially expressed genes affecting polyunsaturated fatty acids percentage in the Huangshan Black chicken population. *PLoS One.* 2018;13(4):e0195132. Epub 2018/04/20. doi: 10.1371/journal.pone.0195132. PubMed PMID: 29672513; PubMed Central PMCID: PMCPMC5908183.

37. Petit MM, Schoenmakers EF, Huysmans C, Geurts JM, Mandahl N, Van de Ven WJ. LHFP, a novel translocation partner gene of HMGIC in a lipoma, is a member of a new family of LHFP-like genes. *Genomics*. 1999;57(3):438-41. Epub 1999/05/18. doi: 10.1006/geno.1999.5778. PubMed PMID: 10329012.
38. Dahlén A, Debiec-Rychter M, Pedeutour F, Domanski HA, Höglund M, Bauer HC, et al. Clustering of deletions on chromosome 13 in benign and low-malignant lipomatous tumors. *Int J Cancer*. 2003;103(5):616-23. Epub 2002/12/21. doi: 10.1002/ijc.10864. PubMed PMID: 12494468.
39. Lindberg M. *Diagnostic Pathology: Soft Tissue Tumors*; Elsevier; 2019.
40. Pascucci A, Lynch PJ. Lipedema with multiple lipomas. *Dermatol Online J*. 2010;16(9):4. Epub 2010/09/30. PubMed PMID: 20875325.
41. Hansson E, Svensson H, Brorson H. Review of Dercum's disease and proposal of diagnostic criteria, diagnostic methods, classification and management. *Orphanet J Rare Dis*. 2012;7:23. Epub 2012/05/02. doi: 10.1186/1750-1172-7-23. PubMed PMID: 22546240; PubMed Central PMCID: PMC3444313.
42. Herbst KL. Subcutaneous Adipose Tissue Diseases: Dercum Disease, Lipedema, Familial Multiple Lipomatosis, and Madelung Disease. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, et al., editors. *Endotext*. South Dartmouth (MA): MDText.com, Inc. Copyright © 2000-2021, MDText.com, Inc.; 2000.
43. Eisman J, Swezey RL. Juxta-articular adiposis dolorosa: what is it? Report of 2 cases. *Ann Rheum Dis*. 1979;38(5):479-82. Epub 1979/10/01. doi: 10.1136/ard.38.5.479. PubMed PMID: 518149; PubMed Central PMCID: PMC1000398.
44. Naggert JK, Fricker LD, Varlamov O, Nishina PM, Rouille Y, Steiner DF, et al. Hyperproinsulinaemia in obese fat/fat mice associated with a carboxypeptidase E mutation which reduces enzyme activity. *Nat Genet*. 1995;10(2):135-42. Epub 1995/06/01. doi: 10.1038/ng0695-135. PubMed PMID: 7663508.

45. Angst F, Benz T, Lehmann S, Wagner S, Simmen BR, Sandòr PS, et al. Extended overview of the longitudinal pain-depression association: A comparison of six cohorts treated for specific chronic pain conditions. *J Affect Disord.* 2020;273:508-16. Epub 2020/06/21. doi: 10.1016/j.jad.2020.05.044. PubMed PMID: 32560947.
46. Torrance N, Smith BH, Lee AJ, Aucott L, Cardy A, Bennett MI. Analysing the SF-36 in population-based research. A comparison of methods of statistical approaches using chronic pain as an example. *J Eval Clin Pract.* 2009;15(2):328-34. Epub 2009/04/02. doi: 10.1111/j.1365-2753.2008.01006.x. PubMed PMID: 19335493.
47. Barcones-Molero MF, Sánchez-Villegas A, Martínez-González MA, Bes-Rastrollo M, Martínez-Urbistondo M, Santabàrbara J, et al. The influence of obesity and weight gain on quality of life according to the SF-36 for individuals of the dynamic follow-up cohort of the University of Navarra. *Rev Clin Esp (Barc).* 2018;218(8):408-16. Epub 2018/07/01. doi: 10.1016/j.rce.2018.05.005. PubMed PMID: 29958652.
48. Centre for Public Health Excellence at N, National Collaborating Centre for Primary C. National Institute for Health and Clinical Excellence: Guidance. Obesity: The Prevention, Identification, Assessment and Management of Overweight and Obesity in Adults and Children. London: National Institute for Health and Clinical Excellence (UK). Copyright © 2006, National Institute for Health and Clinical Excellence.; 2006.
49. Sahle B, Slewa-Younan S, Melaku Y, Ling L, Renzaho A. A Bi-Directional Association Between Weight Change and Health-Related Quality of Life: Evidence From the 11-year Follow-Up of 9916 Community-Dwelling Adults. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation.* 2020;29(6). doi: 10.1007/s11136-020-02423-7. PubMed PMID: 31938964.
50. Bowling A, Bond M, Jenkinson C, Lamping D. Short Form 36 (SF-36) Health Survey questionnaire: which normative data should be used? Comparisons between the norms provided by the Omnibus Survey

in Britain, the Health Survey for England and the Oxford Healthy Life Survey. *Journal of Public Health*. 1999;21(3):255-70. doi: 10.1093/pubmed/21.3.255.

Figure 1

Figure 2

Investigation of clinical characteristics and genome associations in the ‘UK Lipoedema’ cohort

Grigoriadis *et al.*

Supplementary Methods

Case ascertainment

The diagnosis of lipoedema and recruitment to the study used the following inclusion and exclusion criteria based on consensus opinions of clinical experts.

List of inclusion criteria (as summarized in Table 1)

- Female.
- Age of onset (ideally below 35 years).
- BMI ≤ 40 kg/m².
- Waist-hip ratio (WHR) $\leq 0.85^*$.
- No or minimal central (android) obesity.
- Bilateral and symmetrical fat hypertrophy on lower limbs (e.g. “saddlebags” fat distribution on hips or steatopygia, medial knee “fat pads”), usually soft and “doughy”/“floppy” to the touch.
- Spared feet.
- Persistent enlargement (with no significant effect from overnight elevation)
- White British ethnicity (only applicable for the GWAS).

*The WHO advises that a healthy WHR is ≤ 0.85 for women [1], WHR > 0.85 indicates abdominal obesity.

Individuals were excluded from the study if any of the following criteria were identified.

List of exclusion criteria

- Lymphoedema skin changes (hyperkeratosis or papillomatosis).
- Firm, fibrotic swelling suggesting chronic lymphoedema.
- History of episodes of acute cellulitis.
- No significant comorbidities (e.g. diabetes or renal disease).
- Morbid obesity

Each patient was carefully assessed through clinical examination and face-to-face interview and a general detailed medical history was taken and data collected on:

- weight, height, BMI
- waist and hip circumference, WHR
- family history of lipoedema
- arm swelling
- hypermobility
- age of onset of lipoedema
- age of puberty
- limb volume response to dieting
- easy bruising of affected areas
- tenderness or pain
- history or presence of venous disease (self-reported and inspected)
- history or presence of orthostatic oedema (self-reported and inspected)

Clinical summaries, including medical photographs obtained with patient consent, were reviewed by at least two specialists, and all available medical case files studied. Patients whose BMI was above 40 kg/m² or WHR above 0.85 at the time of the recruitment consultation were included in the study, but only if they had been known to the senior clinician for several years and historically would have fallen within the inclusion criteria. If the patient was new to our service and did not fulfil the major inclusion criteria, they were not included in the analyses.

The waist was measured in centimetres at the narrowest part of the abdomen usually close to the umbilicus. The hips were measured (in cm) by locating the greater trochanter of the femur and measuring at that level, usually the widest portion of the buttocks. Waist-hip ratio (WHR) was then calculated as the waist circumference divided by hip circumference.

Some of the data collected need to be interpreted with caution as they included subjective measures based on self-reporting, such as easy bruising, tenderness/pain and response to diet. For example, the responsiveness to diet was assessed through the question *“If responsive to dieting and there is weight loss; is it disproportionate with less weight lost from legs (and arms) than the rest of the body?”*. However, the perception of what dieting and weight-loss entails can be subjective, and we had no means of following up on this.

Age of onset of lipoedema is self-reported in most cases. Disease duration was calculated by subtracting the age of onset from age at recruitment date.

Hypermobility or joint laxity was checked at elbows, knees, small joints of the hands and back (Beighton score). If hypermobile in four or more joints, the recruit was scored as hypermobile.

Venous problems were assessed through clinical assessment and categorized into ‘mild superficial’ (equivalent to CEAP C1) and ‘uncomplicated varicose veins’ (equivalent to CEAP C2). A few cases self-reported having undergone surgery for varicose veins (classed as CEAP C3). However, chronic venous disease was not formerly assessed with e.g. duplex scan. Regarding the assessment of orthostatic

oedema, we did not differentiate between lymphoedema or chronic oedema due to e.g. venous hypertension.

It was also recorded if the patient had undergone liposuction or bariatric surgery. Only cases known to us with clinically confirmed lipoedema prior to these interventions were included in the study.

Supplementary Tables

See supplementary Excel file for spreadsheets for each supplementary table.

S1 Table. Raw data collected for all 200 recruits in the 'UK Lipoedema' cohort. Summarized in Table 2.

S2 Table. Raw SF-36 data for the 135 individuals who answered enough of the 36 questions to be included in the quality of life analysis. Results are summarized in Table 3.

S3 Table. Correlations between SF-36 Quality of life Questionnaire domains. The correlation coefficients, r , are displayed and those with strong correlations ($r > 0.7$) are highlighted in bold type. All correlations were significant at the $p < 0.05$ level.

S4 Table. GEL Participants with Lipoedema as "Recruited Disease" in the Rare Diseases program of the 100,000 Genomes Project. Age at recruitment is calculated as (year of recruitment to GEL) – (Year of Birth). Family history is based on any reports of "Affected" family members in GEL; ".", uncertain.

S5 Table. List of the top 30 variants in the discovery study, and their GWAS results in the replication study and meta-analysis. The variants have been annotated to their nearest genes. Effect sizes and P values are shown for both studies and meta-analysis. Direction column shows whether the discovery and replication study follow the same direction of effect.

S6 Table. List of Genome regulatory elements associated with the three top meta-analysis SNPs (rs1409440, rs7994616, rs11616618) on chromosome 13 potentially associated with lipoedema. Data was downloaded from UCSC Table Browser using the geneHancerClusteredInteractionsDoubleElite (last updated: 2019-01-15) and encodeCcreCombined (last updated: 2020-05-20) tables.

S7 Table. List of all significant gene expression quantitative trait loci found for the SNPs in Table 4 and/or their LD buddies ($P < 5 \times 10^{-6}$, $r^2 > 0.6$). Analysis was performed on LDexpress module from the LDlink online tool of NCBI and this list was downloaded.

S8 Table. List of genes selected for Gene Ontology (GO) enrichment analysis. The genes were either selected because they were directly associated with the SNPs potentially associated with lipoedema (intragenic SNPs from Table 4) or because they are associated with the SNPs in Table 4 through eQTL ($r^2 > 0.6$, $P < 5 \times 10^{-6}$) as summarised in S7 Table.

S9 Table. Gene Ontology (GO) enrichment analysis on the genes directly and/or indirectly associated with the SNPs potentially associated with lipoedema (list from S8 Table). The analysis was performed on Biological Process (BP), Molecular Function (MF), and Cellular Component (CC) GO terms.

Supplementary Figures

S1 Fig. Distribution of BMI, WHR and waist circumference. Of the 200 lipoedema cases recruited to the 'UK Lipoedema' cohort, we have anthropometric data for 161 (A and C). 130 individuals of white British descent were selected for GWAS of which 105 have been plotted in (B and D). (A, B) Waist circumference vs BMI show that many individuals fall in the overweight (BMI over 25 kg/m²; yellow line) and obese (BMI over 30 kg/m²; red line) categories. According to the NHS waist measurement guidelines for white European women, a waistline < 80cm is low risk (in green), high risk 80–88cm (in blue) and very high risk > 88cm (in red) of developing diseases such as type 2 diabetes, hypertension, coronary heart disease, cancer and stroke [48]. (C, D) Waist-hip ratio (WHR) vs BMI show that the majority of cases included in the study have a WHR < 0.85, which according to WHO guidelines is healthy [35]. Any cases outside the region of inclusion, i.e. the cases with a WHR > 0.85 (and BMI > 40), have been carefully investigated by the clinicians involved before being included in the study (see Supplementary Methods for details on case ascertainment).

A

B

1 **S2 Fig.** Radar diagram showing the mean score for each of the 8 domains from the SF-36
2 Quality of Life questionnaire in lipoedema patients taken from Table 3 (red). The lipoedema
3 cases are comparatively similar to patients with chronic neuropathic pain (blue, SF36 data
4 taken from Torrance *et al.* [3]). In contrast, overweight female without lipoedema (yellow,
5 Sahle *et al.* [4]) are similar on many domains to healthy weight female (light green, Sahle *et*
6 *al.* [4]; or dark green, Bowling *et al.* [5]), whilst obese female without lipoedema (orange,
7 Sahle *et al.* [4]) show a lower score on some domains but not as low as the lipoedema cases.
8 The healthy females from Bowling *et al.* (dark green; [5]) are age matched to the lipoedema
9 cases, whereas the data from Sahle *et al.* [4] include males. The data on patients with chronic
10 pain were taken from a general population of over 18 years old attending their GP service [3].

11

Supplementary References

1. WHO. Waist circumference and waist-hip ratio : report of a WHO expert consultation, Geneva, 8-11 December 2008: World Health Organization; 2011.
2. Centre for Public Health Excellence at N, National Collaborating Centre for Primary C. National Institute for Health and Clinical Excellence: Guidance. Obesity: The Prevention, Identification, Assessment and Management of Overweight and Obesity in Adults and Children. London: National Institute for Health and Clinical Excellence (UK) Copyright © 2006, National Institute for Health and Clinical Excellence.; 2006.
3. Torrance N, Smith BH, Lee AJ, Aucott L, Cardy A, Bennett MI. Analysing the SF-36 in population-based research. A comparison of methods of statistical approaches using chronic pain as an example. *J Eval Clin Pract*. 2009;15(2):328-34. Epub 2009/04/02. doi: 10.1111/j.1365-2753.2008.01006.x. PubMed PMID: 19335493.
4. Sahle B, Slewa-Younan S, Melaku Y, Ling L, Renzaho A. A Bi-Directional Association Between Weight Change and Health-Related Quality of Life: Evidence From the 11-year Follow-Up of 9916 Community-Dwelling Adults. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation*. 2020;29(6). doi: 10.1007/s11136-020-02423-7. PubMed PMID: 31938964.
5. Bowling A, Bond M, Jenkinson C, Lamping D. Short Form 36 (SF-36) Health Survey questionnaire: which normative data should be used? Comparisons between the norms provided by the Omnibus Survey in Britain, the Health Survey for England and the Oxford Healthy Life Survey. *Journal of Public Health*. 1999;21(3):255-70. doi: 10.1093/pubmed/21.3.255.